Cellect Biotechnology Ltd | |||||||||||
Consolidated Cash Flow Data | |||||||||||
Convenience | |||||||||||
translation | |||||||||||
Six months ended | Six months ended | Three months ended | |||||||||
June 30, | June 30, | June 30, | |||||||||
2019 | 2019 | 2018 | 2019 | 2018 | |||||||
Unaudited | Unaudited | ||||||||||
U.S. dollars | NIS | ||||||||||
(In thousands) | |||||||||||
Cash flows from operating activities: | |||||||||||
Total comprehensive loss | (1,660) | (5,919) | (9,564) | (816) | (5,989) | ||||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
Net financing expenses | 229 | 815 | (837) | 443 | (314) | ||||||
Loss (gain) from revaluation of financial assets presented at fair value through profit and loss | 2 | 6 | (148) | 2 | (148) | ||||||
Depreciation | 54 | 192 | 215 | 94 | 110 | ||||||
Changes in fair value of traded and not traded warrants | (2,368) | (8,442) | (1,888) | (5,895) | 608 | ||||||
Share-based payment | 148 | 529 | 2,184 | 744 | 937 | ||||||
Decrease (increase) in other receivables | 40 | 145 | (87) | 75 | (150) | ||||||
Increase (decrease) in other payables | (201) | (715) | (1,115) | (730) | (204) | ||||||
Decrease in right-of-use assets | 89 | 314 | - | 200 | - | ||||||
Interest received during the period | (13) | (46) | (15) | (46) | (15) | ||||||
Net cash used in operating activities | (3,680) | (13,121) | (11,255) | (5,929) | (5,165) | ||||||
Cash flows from investing activities: | |||||||||||
Short term deposits, net | - | - | (3,503) | - | (3,503) | ||||||
Restricted deposit, net | - | - | (28) | - | 135 | ||||||
Sales of marketable securities measured at fair value through profit and loss | - | - | 8,498 | - | 3,998 | ||||||
Purchase of property, plant and equipment | (34) | (120) | (228) | - | (88) | ||||||
Net cash provided by investing activities | (34) | (120) | 4,739 | - | 542 | ||||||
Cash flows from financing activities: | |||||||||||
Exercise of warrants and stock options into shares | - | - | 399 | - | - | ||||||
Leases liabilities | (77) | (278) | - | (178) | - | ||||||
Issue of share capital and warrants, net of issue costs | 6,653 | 23,723 | 12,360 | (1,114) | (5) | ||||||
Net cash provided (used) by financing activities | 6,576 | 23,445 | 12,759 | (1,292) | (5) | ||||||
Exchange differences on balances of cash and cash equivalents | (216) | (769) | 852 | (397) | 329 | ||||||
Increase (decrease) in cash and cash equivalents | 2,646 | 9,435 | 7,095 | (7,618) | (4,299) | ||||||
Balance of cash and cash equivalents at the beginning of the period | 4,994 | 17,809 | 13,734 | 34,862 | 25,128 | ||||||
Balance of cash and cash equivalents at the end of the period | 7,640 | 27,244 | 20,829 | 27,244 | 20,829 | ||||||
